Literature DB >> 2487035

Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.

G Ochs1, A Struppler, B A Meyerson, B Linderoth, J Gybels, B P Gardner, P Teddy, A Jamous, P Weinmann.   

Abstract

Twenty eight patients with severe, intractable spasticity have been treated by chronic intrathecal administration of baclofen. An implantable programmable drug-administration-device (DAD) was used with a permanent intrathecal catheter. Infusion of 50 to 800 micrograms/day of baclofen completely abolished spasticity. Follow-up was up to two years. Therapeutic effect was documented by clinical assessment of tone, spasms and reflexes and by electrophysiological recordings of mono- and polysynaptic reflex activity. Complications and untoward side-effects of the procedure were few. This procedure is recommended for spasticity of spinal origin refractory to physiotherapy and oral medication. It is a preferable alternative to ablative surgical intervention.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2487035      PMCID: PMC1031830          DOI: 10.1136/jnnp.52.8.933

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  The effect of intrathecal baclofen on electrical muscle activity in spasticity.

Authors:  H Müller; J Zierski; D Dralle; U Börner; O Hoffmann
Journal:  J Neurol       Date:  1987-06       Impact factor: 4.849

2.  A new agent for the control of spasticity.

Authors:  R F Jones; D Burke; J E Marosszeky; J D Gillies
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-08       Impact factor: 10.154

3.  Baclofen is antinociceptive in the spinal intrathecal space of animals.

Authors:  P R Wilson; T L Yaksh
Journal:  Eur J Pharmacol       Date:  1978-10-15       Impact factor: 4.432

4.  Chronic intrathecal morphine for intractable pain.

Authors:  R D Penn; J A Paice
Journal:  J Neurosurg       Date:  1987-08       Impact factor: 5.115

5.  Time course of clinical and physiological effects of stimulation of the cerebellar surface in patients with spasticity.

Authors:  D L McLellan; M Selwyn; I S Cooper
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-02       Impact factor: 10.154

6.  The effect of epidural application of opioids on spasticity of spinal origin.

Authors:  A Struppler; B Burgmayer; G B Ochs; H G Pfeiffer
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

7.  Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis.

Authors:  E Knutsson; U Lindblom; A Mårtensson
Journal:  J Neurol Sci       Date:  1974-11       Impact factor: 3.181

8.  Reduced spinal reflexes following intrathecal baclofen in the rabbit.

Authors:  J S Kroin; R D Penn; R L Beissinger; R C Arzbaecher
Journal:  Exp Brain Res       Date:  1984       Impact factor: 1.972

9.  Present state of extradural and intrathecal opioid analgesia in Sweden. A nationwide follow-up survey.

Authors:  N Rawal; S Arnér; L L Gustafsson; R Allvin
Journal:  Br J Anaesth       Date:  1987-06       Impact factor: 9.166

10.  Effects of intravenously administered enantiomers of baclofen on functionally identified units in lumbar dorsal horn of the spinal cat.

Authors:  J L Henry
Journal:  Neuropharmacology       Date:  1982-11       Impact factor: 5.250

View more
  16 in total

Review 1.  Evidence basis for treatment of spasticity.

Authors:  D M Dawson
Journal:  Curr Neurol Neurosci Rep       Date:  2001-11       Impact factor: 5.081

Review 2.  Intrathecal drug administration. Present use and future trends.

Authors:  J S Kroin
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

3.  Intrathecal baclofen for treatment of spasticity.

Authors:  J Vanneste; P Augustijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-08       Impact factor: 10.154

4.  Trends in the pathophysiology and pharmacotherapy of spasticity.

Authors:  J Noth
Journal:  J Neurol       Date:  1991-06       Impact factor: 4.849

5.  Clinical and neurophysiologic assessment of strength and spasticity during intrathecal baclofen titration in incomplete spinal cord injury: single-subject design.

Authors:  Mark Bowden; Dobrivoje S Stokic
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

6.  Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen.

Authors:  J Dressnandt; B Conrad
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

7.  Accidental intoxication with 60 mg intrathecal baclofen: survived.

Authors:  Benjamin Berger; Barbara Vienenkoetter; Mirjam Korporal; Andrea Rocco; Hans-Michael Meinck; Thorsten Steiner
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

8.  Intraspinal baclofen in the treatment of severe spasticity and spasms.

Authors:  J Sahuquillo; T Muxi; M Noguer; R Jodar; C Closa; E Rubio; L Garcia-Fernandez; J M Guitart
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

Review 9.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Intrathecal baclofen: Its effect on symptoms and activities of daily living in severe spasticity due to spinal cord injuries: A pilot study.

Authors:  Yogendrasinh Jagatsinh
Journal:  Indian J Orthop       Date:  2009-01       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.